The company was established in 2000 and listed on the KOSDAQ market in 2005. It is engaged in the business of cord blood storage, sales of health functional foods, and the development and sales of stem cell therapies. It is the leading cord blood bank operator in Korea. Its R&D pipeline includes Cartistem, a treatment for knee osteoarthritis; Pneumostem, a treatment for bronchopulmonary dysplasia; and Neurostem, a treatment for Alzheimer's disease. The company owns MEDIPOST America and Immunique as its consolidated subsidiaries.

Regenerative Medicine through cutting-edge stem cell platform technology : Umbilical Cord Blood-derived Mesenchymal Stem Cells (UCB-MSCs), are types of adult stem cells which can promote regeneration of damaged tissues and their functions by secreting various therapeutic proteins within the patient’s disease environment, and may become a treatment option for various incurable diseases.

Public

Biotech, R&D Service